Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Quest Diagnostics Incorporated(DGX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for DGX
10/28/2026: DGX (3-star) is a STRONG-BUY. BUY for 2 days. Simulated Profits (1.26%). Updated daily EoD!
Quest Diagnostics is a primary US provider of diagnostic information services, offering essential clinical, pathology, and wellness testing to patients and physicians. The company benefits from a massive nationwide network and deep integration with electronic health records, which provides a resilient foundation for its business. Its growth strategy centers on expanding into higher-margin molecular and specialty testing. However, the company faces risks from potential government reimbursement cuts, competition from hospital-based laboratories, and technological disruption from point-of-care testing. It is a stable, dividend-paying stock that may suit value and income-oriented investors seeking a defensive healthcare position.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers steady, predictable growth rather than rapid, high-alpha expansion. |
| Momentum investor | Weak fit | The stock generally tracks industry trends rather than exhibiting high-velocity momentum shifts. |
| Value investor | Strong fit | The company often trades at reasonable multiples relative to its stable, essential service business model. |
| Dividend investor | Strong fit | Consistent cash flow and a reliable dividend history make it attractive for income-focused portfolios. |
| Low-risk investor | Strong fit | Its role as an essential healthcare provider provides defensive characteristics during market volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Low | The stock is generally less volatile than the broader market due to its defensive nature. |
| Valuation risk | Medium | Market pricing of healthcare services remains sensitive to policy and interest rate changes. |
| Competition risk (Pricing and scale) | Medium | Pressure from Labcorp and hospital systems can impact pricing power. |
| Business quality | Strong | The company operates a resilient, essential infrastructure for the US healthcare system. |
| Dividend income | Strong | Stable cash flows support sustained dividend distributions. |
| Execution risk | Medium | Integrating regional acquisitions effectively is critical for maintaining margins. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type Stock | Historic Profit 6.72% | Avg. Invested days 43 | Today’s Advisory Strong Buy |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/28/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 26.77B USD | Price to earnings Ratio 24.06 | 1Y Target Price 256.6 |
Price to earnings Ratio 24.06 | 1Y Target Price 256.6 | ||
Volume (30-day avg) 1.1M shares | Beta 0.54 | 52 Weeks Range 168.34 - 249.73 | Updated Date 10/27/2026 |
52 Weeks Range 168.34 - 249.73 | Updated Date 10/27/2026 | ||
Dividends yield (FY) 1.39% | Basic EPS (TTM) 10.08 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Testing Services | Routine and specialty blood and pathology testing. | This is the core engine of the company, charging for tests performed on millions of patients annually. |
| Health & Wellness | Employer-based screening and consumer-initiated lab testing. | This is a growth area focused on proactive health management outside of traditional doctor visits. |
| Geographic Exposure | United States domestic markets. | The company operates almost exclusively in the US, making it sensitive to US healthcare policy. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2026-10-22 | When Before Market | Estimate 2.85 | Actual 3 |
Profitability
Profit Margin 9.54% | Operating Margin (TTM) 15.63% |
Management Effectiveness
Return on Assets (TTM) 6.61% | Return on Equity (TTM) 15.32% |
Valuation
Trailing PE 24.06 | Forward PE 20.24 | Enterprise Value 32.26B | Price to Sales(TTM) 2.26 |
Enterprise Value 32.26B | Price to Sales(TTM) 2.26 | ||
Enterprise Value to Revenue 2.73 | Enterprise Value to EBITDA 13.86 | Shares Outstanding 110.37M | Shares Floating 109.46M |
Shares Outstanding 110.37M | Shares Floating 109.46M | ||
Percent Insiders 0.43 | Percent Institutions 99.09 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.